May 2006

Contents

Editorial

• Volume 7 Number 5 May 2006

Conference reports

• 12th Annual Conference of the British HIV Association, 29 March–-1 April 2006, Brighton

• HIV in the UK – summaries from BHIVA 12th annual conference

• Primary care practice still fails to diagnose HIV patients from high-risk groups or with symptomatic acute infection

• Use of HLA-B*5701 genetic testing to reduce abacavir hypersensitivity reactions

• Dosing rifabutin and lopinavir/r – sub-optimal rifabutin levels reported in five patients dosed according to current guidelines

• Fatal seronegative visceral leishmaniasis in Portuguese patient

• Awareness of PEP after sexual exposure (PEPSE)

• Final reports from 13th Conference on Retroviruses and Opportunistic Infections (CROI), 5-8 February 2006, Denver

• Regimen durability and toxicity in 36-month follow up on ART in Khayelitsha, South Africa

• Adults in resource-limited settings are most likely to experience an HIV-associated Illness in the first three months from initiating therapy

• Causes of death in adults receiving ARV therapy in Senegal

• Rapid scale-up of treatment in Zambia delivered at primary health level

• The effect of HIV subtype on disease progression in Rakai, Uganda

• Genital tract pharmacokinetics of ten antiretroviral drugs in HIV-positive women

• Initiation of ART leads to a rapid decline in cervical and vaginal HIV-1 RNA

• Effect of HSV-2 treatment on HIV-1 genital shedding and plasma viral load

• Once-daily FTC, ddI, and efavirenz in children and adolescents

• Simplified triple NRTI regimen effective in vertically infected children: two years follow-up

• Long-term clinical and biological outcomes in children vertically infected with HIV

• Prospective follow up of children with lipodystrophy

• Tuberculosis in HIV-positive children often missed from incidence data: the influence of HAART on paediatric TB

• Nevirapine pharmacokinetics with infant prophylaxis

• Prevention of rectal transmission of SIV in macaques using FTC with tenofovir: FTC has independent protective effect even as monotherapy

• K65R frequently emerges within 1-6 weeks of tenofovir monotherapy in macaques

• A genome armed against HIV

• Circumcision: a surprising benefit from an unkind cut

• Topical microbicides: the real front line of HIV prevention

• Prevention of rectal transmission of SIV in macaques using FTC with tenofovir: FTC has independent protective effect even as monotherapy

Antiretrovirals

• Development of d-d4FC (dexelvucitabine, Reverset) discontinued

Treatment access

• Lopinavir/r (meltrex) filed in South Africa

• Indian community organisations file first opposition against patent application

• ITPC Indian Mailbox database now online

• Global fund review: timing of Round 6 still unclear

Other news

• Letter from Sir Liam Donaldson to all Chief Executives of Primary Care Trusts and Strategic Health Authorities in England

• Knowledge about HIV transmission in the UK declined over last five years

• Volunteer opportunity: improve healthcare for HIV-positive children in developing countries

On the web

• Microbicides 2006 Conference, 23-26 April 2006, Cape Town, South Africa

• HIV inSite Knowledge Base: new and updated chapters and lectures

• Johns Hopkins pocket guide to HIV & AIDS treatment

PDFs

• Volume 7 Number 5 May 2006 PDF